Shire, a global, biopharmaceutical company headquartered in Ireland, has completed a $32 billion acquisition of Baxalta, marketer of the Aralast NP and Glassia brand augmentation therapies for Alphas.
Baxalta – which is now an indirect, wholly owned subsidiary of Shire – markets in its specialty areas of hematology, immunology and oncology, and will continue to produce Alpha-1 augmentation therapies.
“On behalf of the Alpha-1 Foundation, I would like to congratulate Shire on its acquisition of Baxalta and welcome them to the Alpha-1 Community,” said Henry Moehring, President and CEO of the Foundation. “We have enjoyed a great working relationship with Baxalta; now that they are part of Shire, we look forward to continuing that relationship for the benefit of people affected by Alpha-1 Antitrypsin Deficiency worldwide.”
Shire currently markets products in gastrointestinal/endocrine diseases, hereditary angioedema (HAE), neuroscience, and lysosomal storage diseases.
The combined company will consist of more than 22,000 employees across more than 100 countries, as well as more than 50 programs in clinical development, balanced across early-, mid-, and late-stage projects.
“Upon the completion of our combination with Baxalta, Shire is now the global leader in rare diseases, with the number one rare diseases platform based on both revenue and pipeline programs,” Shire CEO Flemming Ornskov, MD, MPH said in a statement.
Ornskov told The Boston Globe that Shire is seeking to expand at least one of the combined company’s facilities – the R&D site opened by Baxalta last December at Kendall Square in Cambridge, MA, by adding 100 to 200 employees to the site’s workforce of more than 400.
Baxalta is the former Baxter BioScience global biopharmaceutical business spun off in July of 2015 by Baxter International, with a focus on developing new treatments for people with orphan diseases and underserved conditions in three areas of therapeutic focus.
Baxalta is expected to be redomiciled in Dublin, where Shire is based – and where corporate taxes are much lower than in the U.S. Baxalta had been headquartered in Deerfield, IL, the headquarters city of Baxter.
As a result of the merger, the appointments of Baxalta board members Gail D. Fosler and Albert P.L. Stroucken to Shire’s board as nonexecutive directors have taken effect, Shire said.
“As we launch our combined company today, we have a talented and experienced extended leadership team in place to guide the organization in achieving our goals,” Ornskov added. “Working together, the possibilities are tremendous for our patients, healthcare partners, and, importantly, our people, with opportunity for additional value creation for our shareholders.”
To read the full press release about the merger, click here.